Nebula Research & Development LLC Purchases Shares of 9,556 Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Nebula Research & Development LLC purchased a new stake in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 9,556 shares of the company’s stock, valued at approximately $440,000.

Other hedge funds have also bought and sold shares of the company. R Squared Ltd acquired a new position in Establishment Labs during the 4th quarter valued at approximately $36,000. KLP Kapitalforvaltning AS purchased a new stake in shares of Establishment Labs in the 4th quarter valued at $161,000. Hood River Capital Management LLC boosted its holdings in shares of Establishment Labs by 236.4% in the 4th quarter. Hood River Capital Management LLC now owns 5,920 shares of the company’s stock valued at $273,000 after acquiring an additional 4,160 shares during the last quarter. Handelsbanken Fonder AB boosted its holdings in shares of Establishment Labs by 32.3% in the 4th quarter. Handelsbanken Fonder AB now owns 8,200 shares of the company’s stock valued at $378,000 after acquiring an additional 2,000 shares during the last quarter. Finally, SkyView Investment Advisors LLC boosted its holdings in shares of Establishment Labs by 30.5% in the 3rd quarter. SkyView Investment Advisors LLC now owns 12,000 shares of the company’s stock valued at $519,000 after acquiring an additional 2,805 shares during the last quarter. Institutional investors and hedge funds own 72.91% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Needham & Company LLC assumed coverage on shares of Establishment Labs in a report on Monday, April 14th. They issued a “hold” rating on the stock. Stephens reaffirmed an “overweight” rating and issued a $52.00 price objective on shares of Establishment Labs in a report on Thursday, March 6th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $57.40.

Establishment Labs Stock Performance

Shares of NASDAQ ESTA opened at $30.26 on Wednesday. The company’s fifty day moving average price is $35.86 and its 200 day moving average price is $39.08. Establishment Labs Holdings Inc. has a 1 year low of $26.56 and a 1 year high of $60.12. The company has a market capitalization of $872.88 million, a PE ratio of -11.73 and a beta of 0.77. The company has a debt-to-equity ratio of 5.94, a quick ratio of 2.29 and a current ratio of 3.62.

Establishment Labs (NASDAQ:ESTA) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.34). Establishment Labs had a negative return on equity of 184.55% and a negative net margin of 46.13%. The firm had revenue of $44.51 million for the quarter, compared to analysts’ expectations of $44.45 million. On average, research analysts predict that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current year.

Establishment Labs Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.